Management of patients with uncontrolled arterial hypertension - the role of electronic compliance monitoring, 24 hour ambulatory blood pressure monitoring and candesartan/hydrochlorothiazide (HCTZ)
Completed
- Conditions
- Resistant arterial hypertensionCirculatory SystemHypertension
- Registration Number
- ISRCTN02311110
- Lead Sponsor
- Astra Zeneca (Germany)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 62
Inclusion Criteria
Patients with essential hypertension and office Blood Pressure (oBP) more than or equal to 140/90 mmHg, despite combination therapy (more than two antihypertensive drugs)
Exclusion Criteria
1. Pregnancy
2. Known intolerance of HCTZ or Angiotensin II Type One Receptor Blockers (AT1-Blockers)
3. Secondary hypertension
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Drug compliance<br>2. Blood pressure
- Secondary Outcome Measures
Name Time Method ot provided at time of registration